Commercialization


  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images

    Antitrust watchdogs have pharma in their sights, and the landscape is getting thornier

    The FTC and DOJ are heightening antitrust enforcement, and pharma deals are a prime target.

    By Feb. 2, 2023
  • Yesmean Wahdan Bayer
    Image attribution tooltip
    Permission granted by Yesmean Wahdan Bayer
    Podcast

    Woman of the Week: Bayer’s Dr. Yesmean Wahdan

    The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

    By Feb. 1, 2023
  • booster
    Image attribution tooltip
    Stock via Getty Images

    Vaxxinity eyes global COVID-19 vaccine market with ‘next-gen’ booster

    The biotech aims to complete rolling submissions with regulators in the U.K. and Australia in the first half of 2023.

    By Alexandra Pecci • Jan. 31, 2023
  • Teens in circle holding smart mobile phones of different colors.
    Image attribution tooltip
    Stock via Getty Images

    Patients are using social media — clinical trial experts can learn from that

    Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights. 

    By Jan. 30, 2023
  • scale
    Image attribution tooltip
    Stock via Getty Images

    Weight loss drugs: the promise and pitfalls

    GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

    By Kelly Bilodeau • Jan. 30, 2023
  • Woman relaxing on sofa, enjoying web surfing information in internet
    Image attribution tooltip

    Fizkes/Shutterstock.com

    Sponsored by LiveWorld

    Boost returns from social strategies with new channels and tactics

    Emerging channels offer new ways to reach key targets and improve campaign ROI.

    Jan. 30, 2023
  • A brown building with white vertical sign with the Twitter logo
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    With Twitter in flux, pharma is turning to alternative social spaces

    Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Q&A

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium
    Podcast

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

    By Jan. 25, 2023
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images

    AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

    A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

    By Jan. 24, 2023
  • A prescription bottle with white pills and a wooden gavel sit atop a $100 bill showing Benjamin Franklin's face.
    Image attribution tooltip
    Bill Oxford via Getty Images

    Drug price negotiations: 5 key dates to watch

    As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

    By Kelly Bilodeau • Jan. 23, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Q&A

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    By Jan. 23, 2023
  • Doctor in clinic
    Image attribution tooltip

    Jacob Lund/Shutterstock.com

    Sponsored by LiveWorld

    Tactics for growing your walled garden presence

    Cultivate relationships with HCPs in gated social platforms with content that will thrive.

    Jan. 23, 2023
  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images

    FDA’s 2022 drug approvals fall short of recent norms

    The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

    By Alexandra Pecci • Jan. 19, 2023
  • Novavax vaccine
    Image attribution tooltip
    Carsten Koall via Getty Images

    After ‘limping along,’ Novavax sees a path forward

    With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

    By Jan. 18, 2023
  • Twitter headquarters stands on 10th Street on November 4, 2022 in San Francisco, California.
    Image attribution tooltip
    David Odisho via Getty Images

    Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

    A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

    By Dec. 16, 2022
  • Vicki Goodwin Exelexis
    Image attribution tooltip
    Permission granted by Exelexis’ Dr. Vicki Goodman
    Podcast

    Woman of the Week: Exelixis’ Dr. Vicki Goodman

    With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

    By Dec. 14, 2022
  • arrow change
    Image attribution tooltip
    Stock via Getty Images
    Q&A // First 90 Days

    Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

    With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

    By Dec. 9, 2022
  • The front entrance of the Food And Drug Administration headquarters building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    An FDA proposal could make OTC switches easier. Here’s what the industry has to say

    How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.

    By Dec. 5, 2022
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical

    Executive changes at Teva, Eversana could spell commercial growth in the new year

    With their latest personnel moves, these life sciences companies are preparing for major business shifts.

    By Nov. 23, 2022
  • Close up of a woman's hand holding a smart phone with a heart icon.
    Image attribution tooltip
    iStock via Getty Images

    4 pioneering social media campaigns in pharma this year

    The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

    By Nov. 17, 2022
  • diagram of man, doctor, phone, tablet
    Image attribution tooltip
    Retrieved from Google image.

    While DCTs get all the hype, some industry insiders say the future is a digital hybrid

    Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

    By Nov. 1, 2022
  • Diane Stroehman pix
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann

    The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.

    By Oct. 26, 2022
  • Doug langa head shot
    Image attribution tooltip
    Permission granted by Doug Langa

    Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

    The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

    By Oct. 25, 2022
  • Medicine bottles
    Image attribution tooltip
    Jackfoto via Getty Images

    Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning

    In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.

    By Oct. 24, 2022